BR112022022241A2 - Composição compreendendo albumina para uso no tratamento de esclerose lateral amiotrófica (als) através de troca de plasma - Google Patents
Composição compreendendo albumina para uso no tratamento de esclerose lateral amiotrófica (als) através de troca de plasmaInfo
- Publication number
- BR112022022241A2 BR112022022241A2 BR112022022241A BR112022022241A BR112022022241A2 BR 112022022241 A2 BR112022022241 A2 BR 112022022241A2 BR 112022022241 A BR112022022241 A BR 112022022241A BR 112022022241 A BR112022022241 A BR 112022022241A BR 112022022241 A2 BR112022022241 A2 BR 112022022241A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- als
- albumin
- treatment
- lateral sclerosis
- Prior art date
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title abstract 6
- 102000009027 Albumins Human genes 0.000 title abstract 3
- 108010088751 Albumins Proteins 0.000 title abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
COMPOSIÇÃO COMPREENDENDO ALBUMINA PARA USO NO TRATAMENTO DE ESCLEROSE LATERAL AMIOTRÓFICA (ALS) ATRAVÉS DE TROCA DE PLASMA. A presente invenção refere-se a uma composição compreendendo albumina para uso no tratamento de Esclerose Lateral Amiotrófica (ALS), onde a composição é administrada ao paciente através de troca de plasma usando um volume da dita composição equivalente a aproximadamente 100% do volume de retirada de plasma do paciente, e com uma frequência de duas vezes por semana nas primeiras 3 semanas e uma vez por semana nas seguintes 21 semanas, para um período total de 24 semanas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382375.2A EP3906938A1 (en) | 2020-05-07 | 2020-05-07 | Composition comprising albumin for use in the treatment of amyotrophic lateral sclerosis (als) by plasma exchange |
| PCT/EP2021/060920 WO2021224058A1 (en) | 2020-05-07 | 2021-04-27 | Composition comprising albumin for use in the treatment of amyotrophic lateral sclerosis (als) by plasma exchange |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022022241A2 true BR112022022241A2 (pt) | 2022-12-20 |
Family
ID=70779639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022022241A BR112022022241A2 (pt) | 2020-05-07 | 2021-04-27 | Composição compreendendo albumina para uso no tratamento de esclerose lateral amiotrófica (als) através de troca de plasma |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230158120A1 (pt) |
| EP (2) | EP3906938A1 (pt) |
| JP (1) | JP2023524961A (pt) |
| KR (1) | KR20230007462A (pt) |
| CN (1) | CN115484974A (pt) |
| AR (1) | AR122040A1 (pt) |
| AU (1) | AU2021268454A1 (pt) |
| BR (1) | BR112022022241A2 (pt) |
| CA (1) | CA3177596A1 (pt) |
| CL (1) | CL2022003031A1 (pt) |
| IL (1) | IL297866A (pt) |
| MX (1) | MX2022013764A (pt) |
| TW (1) | TW202207973A (pt) |
| UY (1) | UY39186A (pt) |
| WO (1) | WO2021224058A1 (pt) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2904960A1 (en) * | 2013-03-14 | 2014-10-02 | University Of Florida Research Foundation, Inc. | Di-amino acid repeat-containing proteins associated with als |
| ES2535579B1 (es) * | 2015-01-21 | 2016-02-17 | Grifols Worldwide Operations Limited | Composición que comprende albúmina para su utilización en el tratamiento de Esclerosis Lateral Amiotrófica (ELA) mediante recambio plasmático |
| WO2020018343A1 (en) * | 2018-07-20 | 2020-01-23 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
-
2020
- 2020-05-07 EP EP20382375.2A patent/EP3906938A1/en not_active Withdrawn
-
2021
- 2021-04-27 WO PCT/EP2021/060920 patent/WO2021224058A1/en unknown
- 2021-04-27 US US17/997,730 patent/US20230158120A1/en active Pending
- 2021-04-27 CA CA3177596A patent/CA3177596A1/en active Pending
- 2021-04-27 KR KR1020227042301A patent/KR20230007462A/ko active Search and Examination
- 2021-04-27 CN CN202180032468.7A patent/CN115484974A/zh active Pending
- 2021-04-27 EP EP21720777.8A patent/EP4146250B1/en active Active
- 2021-04-27 IL IL297866A patent/IL297866A/en unknown
- 2021-04-27 JP JP2022566698A patent/JP2023524961A/ja active Pending
- 2021-04-27 AU AU2021268454A patent/AU2021268454A1/en active Pending
- 2021-04-27 BR BR112022022241A patent/BR112022022241A2/pt not_active Application Discontinuation
- 2021-04-27 MX MX2022013764A patent/MX2022013764A/es unknown
- 2021-04-28 UY UY0001039186A patent/UY39186A/es unknown
- 2021-05-05 TW TW110116142A patent/TW202207973A/zh unknown
- 2021-05-07 AR ARP210101259A patent/AR122040A1/es unknown
-
2022
- 2022-11-02 CL CL2022003031A patent/CL2022003031A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4146250B1 (en) | 2024-04-24 |
| TW202207973A (zh) | 2022-03-01 |
| KR20230007462A (ko) | 2023-01-12 |
| IL297866A (en) | 2023-01-01 |
| CN115484974A (zh) | 2022-12-16 |
| AU2021268454A1 (en) | 2023-01-19 |
| WO2021224058A1 (en) | 2021-11-11 |
| EP4146250A1 (en) | 2023-03-15 |
| US20230158120A1 (en) | 2023-05-25 |
| AR122040A1 (es) | 2022-08-03 |
| UY39186A (es) | 2021-11-30 |
| JP2023524961A (ja) | 2023-06-14 |
| CA3177596A1 (en) | 2021-11-11 |
| EP3906938A1 (en) | 2021-11-10 |
| MX2022013764A (es) | 2022-11-30 |
| CL2022003031A1 (es) | 2023-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kruse-Jarres et al. | Surgical experience in two multicenter, open-label phase 3 studies of emicizumab in persons with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2) | |
| WO2021207409A3 (en) | Small molecule inhibitors of sars-cov-2 viral replication and uses thereof | |
| CO6251259A2 (es) | Formulaciones farmaceuticas de estriol en baja dosis | |
| ES2579857T3 (es) | Composiciones de plasma rico en plaquetas | |
| EA200800056A1 (ru) | Каннабиноидный активный фармацевтический ингредиент для лекарственных форм | |
| MX2014000130A (es) | Procedimientos y composiciones para la inhibicion de resorcion osea. | |
| BR112015029918A2 (pt) | uso de alta dose de pridopidina para tratar a doença de huntington | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| ZA202211060B (en) | Anti-viral compounds and methods for administration thereof | |
| Que et al. | Estrogen receptor‑β‑dependent effects of saikosaponin‑d on the suppression of oxidative stress‑induced rat hepatic stellate cell activation | |
| Meltzer et al. | Mometasone furoate nasal spray increases the number of minimal-symptom days in patients with acute rhinosinusitis | |
| Yao et al. | Protective effect of Shenmai injection on knee articular cartilage of osteoarthritic rabbits and IL-1β-stimulated human chondrocytes | |
| Riley et al. | Efficacy and tolerability of high-dose Pelargonium extract in patients with the common cold | |
| PH12021551232A1 (en) | Haloallylamine compounds and application thereof | |
| AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
| Yang et al. | Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19 | |
| MX2021010834A (es) | Compuesto y metodo para la prevencion de transmision del virus de influenza. | |
| BR112022022241A2 (pt) | Composição compreendendo albumina para uso no tratamento de esclerose lateral amiotrófica (als) através de troca de plasma | |
| BR112014004339A2 (pt) | suspensão oral | |
| MX2023005431A (es) | Composicion farmaceutica, formulacion farmaceutica combinada, y kit de formulacion combinada para la prevencion o el tratamiento de la hepatitis b cronica, cada uno que comprende, como ingrediente activo, un agente antiviral oral y una vacuna terapeutica que incluye un lipopeptido y un adyuvante de poli(i:c). | |
| Rodriguez-Cabezas et al. | Priapism associated with iloperidone: a case report | |
| BR112022003687A2 (pt) | Método para tratar tinnitus, composição farmacêutica para administração intranasal, e, dose unitária pulverizável de ocitocina | |
| BR112017022478A2 (pt) | composição farmacêutica de liberação sustentada que contém rivastigmina | |
| Inui et al. | Chemical burn of the tongue resulting from improper use of oral bisphosphonate | |
| BRPI0509305A (pt) | uso de um sensibilizador insulìnico, composição farmecêutica, e , kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing |